Proscia vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Proscia provides a digital pathology platform (Concentriq) that digitizes glass slide workflows and applies AI to accelerate and improve cancer diagnosis; raised $37M including a $25M Series B; FDA-cleared AI applications;
About
Proscia is a Philadelphia-based health technology company founded in 2014 that has developed a digital and computational pathology platform — called Concentriq — designed to transform how pathologists diagnose cancer and how pharmaceutical companies conduct drug discovery research. Pathology has historically been one of the last medical specialties to transition from analog to digital workflows: the standard of care still involves pathologists examining glass microscope slides by hand under optical microscopes. Proscia's Concentriq platform digitizes these glass slides using whole-slide imaging scanners, stores the resulting high-resolution digital images in a cloud-based repository, and provides pathologists with an AI-augmented viewer that can highlight diagnostic features, flag regions of interest, and assist with quantitative analysis that would be time-consuming or impossible to perform manually.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.